- Howard Greenman, Chief Executive Officer
- Dr. Peter Verlander, Chief Scientific Officer
- Dr. Jeffrey Gruneich, VP, Business Development
- Mathew Shaw, Sales
- Christopher Matranga, Internet Marketing
Howard Greenman
Chief Executive Officer
Mr. Greenman was most recently Vice President and Interim CEO for HealthCare IT, Inc. (HCIT) – a biomedical software and services firm specializing in human tissue banking. While at HCIT, he formed partnerships with global pharmaceutical companies as well as major academic medical institutions to standardize the management of donated human specimens by using advanced logistics and clinical data management software and protocols. Prior to HCIT, Mr. Greenman led the strategic marketing function for Philips Medical System's Remote Patient Management Division, part of Philip's New Ventures organization. In this role, Mr. Greenman was responsible for commercialization and partnership strategy for a cardiovascular disease management platform technology. Prior to Philips, Mr. Greenman was Director of Business Development for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available cancer tissue in the world. Mr. Greenman was the founder of medXtend Corporation, a venture backed healthcare services company providing medical devices and services for use by Radiologists and Primary Care Physicians. Additionally, Mr. Greenman worked in a variety of healthcare consulting roles within Accenture's Healthcare Practice, KPMG Peat Marwick's Healthcare Strategy Group, Oracle, and the Boston Consulting Group.
Mr. Greenman holds an M.B.A. from the Wharton School of Business in Healthcare Management.
Dr. Peter Verlander
Chief Scientific Officer
Dr. Verlander was most recently the Associate Director for Strategic Development of the Laboratory for Molecular Medicine (LMM) within the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics, where he helped transform the vision of personalized medicine into reality by translating research discoveries into breakthrough molecular diagnostic tests. Dr. Verlander led the team that developed the first clinical test for detection of EGFR mutations predicting therapeutic response in lung adenocarcinoma. Dr. Verlander is a molecular geneticist with nearly 15 years of experience in various aspects of human genetics in both academia and industry, including research at The Rockefeller University in New York on the molecular genetics of Fanconi anemia (FA), a DNA breakage disorder leading to bone marrow failure and increased risk of leukemia. In 2000, Dr. Verlander came to Boston to join Millennium Predictive Medicine’s Patient Management effort before joining the LMM in 2003.
Dr. Verlander received his PhD in Microbiology from Duke University.
Dr. Jeffrey Gruneich
VP, Business Development
Dr. Gruneich was most recently a World Wide Provider Solution Sales specialist in IBM Healthcare and Life Sciences, focused on translational medicine and biobanking. He worked with government, pharmaceutical, biotechnology, and academic organizations to foster complex relationships and partnerships in support of their strategic goals. As an example, Dr. Gruneich worked closely with a cancer-focused patient advocacy group to identify key strategic objectives which ultimately led them to support and fund a biobanking collaboration between multiple medical centers and researchers across the country. Prior to joining IBM, Dr. Gruneich was Chief Business Officer of Infoceutics, Inc., an anti-microbial bioinformatics company. He also co-founded and was Chief Strategy Officer for eTechtransfer.com, an online exchange for licensing life science intellectual property. He worked as a research scientist developing new immunodiagnostic tests for Charm Sciences.
Dr. Gruneich received his PhD in Bioengineering from the University of Pennsylvania, developing new gene therapy technologies.
Mr. Shaw has nearly ten years of sales experience within the Biotechnology industry. Prior to Provia Labs, he worked over five years as a Clinical Sales Consultant at ViaCord, a leader in cord blood stem cell banking. At ViaCord, he worked closely with families as they made the important decision to bank their child's umbilical cord blood stem cells. Mr. Shaw was involved in sales situations that were escalated as highly competitive, and worked closely with operations and customer service to provide the highest quality level of sales and customer support responsiveness.
Mr. Shaw holds an M.Sc. in Experimental Surgery and a B.Sc. in Anatomy and Cell Biology with a Minor in Management from McGill University in Montreal, Canada.
Christopher Matranga
Internet Marketing
Mr. Matranga brings extensive experience in website production and development, internet marketing strategies, interactive media programs and website analytics. Prior to joining Provia Labs, he served as Web Services Manager at BioBehavioral Diagnostics where he was responsible for the Company's websites, CRM application and managed software vendors. His previous positions include: Web Development Specialist at Ogilvy PR Worldwide, where he performed the entire product lifecycle of creating and launching websites, servicing such clients as National Cancer Institute and Novartis Institutes for BioMedical Research; Webmaster for Ardais Corporation, where he managed the corporate website, intranet and client extranet. He also held positions in Marketing Communications and IT Services in the telecommunications industry.
Mr. Matranga holds B.S. in Business Administration from Rider University.
